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Abstract
The family practitioner in private practice is a key role player within the primary health care system and should play a bigger role in 
national tuberculosis (TB) control. TB training at medical undergraduate level is often not adequate and continuous medical educa-
tion is necessary to develop capacity among private family practitioners. The Department of Health should also encourage the 
involvement of especially the private family practitioners in district TB control, which is a long overdue public-private interaction. This 
article discusses the role of the family practitioner to better diagnose, treat and refer tuberculosis patients. 
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(4):44-50
Epidemiology of tuberculosis
Tuberculosis, normally referred to as TB, is caused by Mycobacterium 
tuberculosis, which was discovered by a German physician called 
Robert Koch in 1882. TB exists everywhere around the globe. During 
the year 2005, 8.8 million TB cases were reported worldwide with 
1.6 million deaths attributed to TB, making TB the single most deadly 
disease. The African continent, with 11% of the world population, 
reported 28% of global TB cases. Although TB incidence has been 
shown to be decreasing in six of the nine World Health Organization 
(WHO) regions, its incidence is still increasing steadily in Africa, 
especially in the Southern African Development Countries (SADC). 
South Africa faces one of the worst tuberculosis epidemics in the 
world1
During the year 2005, South Africa reported 302 467 cases of 
tuberculosis which translates to an incidence rate of 645 per 100 000 
population2. The number of reported cases of tuberculosis increased 
to 342 315 in 2006.2 In South Africa, TB cure rates for new smear-
positive cases (infectious patients) remained low at an average of 
51% (ranging from 45.2% in KwaZulu-Natal to 71.9% in the Western 
Cape)2 at the end of 2005. The WHO recommends a cure rate of 85% 
among all smear-positive pulmonary TB patients (infectious) to control 
TB transmission in any particular country. The rate of patients who 
defaulted on TB treatment was 10.4% in 2005 against a national target 
of 5%.2 The low cure and high defaulter rates have resulted in the 
increase of Multi-Drug Resistant (MDR)-TB caseload in South Africa. 
Between January and October, 2007: 4 951 MDR-TB cases and 481 
Extremely Drug Resistant (XDR)-TB cases were diagnosed in South 
Africa. It costs the state R30 000 or more per patient to treat MDR-TB 
and R300 to treat drug-susceptible TB in South Africa.1
The WHO report issued early in 2008 reiterated the point that the 
treatment success rate for South Africa is low and defaulter rate 
is high when compared to international standards.3 Of the 22 high 
burden countries – defined as those that contribute 80% of the total 
global TB burden – South Africa is ranked seventh and nine of them 
are from Africa.2 A person infected with TB disease in their lungs 
may release tiny particles containing Mycobacterium tuberculosis 
into the air by coughing,4 sneezing or laughing. These particles are 
referred to as droplet nuclei. They are invisible to the naked eye 
and can remain in room air for several hours, until they are removed 
by natural or mechanical ventilation. A person who inhales droplet 
nuclei can become infected with TB.4 Poor socio-economic conditions 
(poverty, overcrowding, poor nutrition) and compromised immune 
status promote its spread. The best way of preventing TB spread is to 
timeously treat all diagnosed cases. 
The main challenges of TB control in Africa are the unknown true 
burden of Drug Resistant (DR)-TB cases, limited laboratory capability 
for TB and drug susceptibility testing (DST), unavailability of second-
line drugs for treatment, high HIV prevalence, inadequate infection 
control procedures and poor drug-resistant tuberculosis monitoring 
and evaluation systems.5 In summary, key challenges facing TB in 
South Africa are the increased defaulter rates, lack of continuous staff 
training, non-decentralisation of laboratory services resulting in the 
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turn-around time remaining far above the target of 48 hours or less, 
inadequate healthcare systems e.g. poorly organised directly observed 
therapy and poor TB infection control management.6
Transmission of TB4
TB affects the lungs commonly but can cause disease in any part of 
the human body. It spreads by airborne route through inhalation of 
droplet nuclei and transmission is affected by:
•  Infectiousness of the patient: This occurs when a patient who is 
already infected has a productive cough. During coughing, several 
droplet nuclei (TB bacilli) escape from the mouth into the air and 
are inhaled by another person. 
•  Environmental conditions: Living with someone infected 
with pulmonary tuberculosis in a place where there is no cross-
ventilation, where windows are small or closed most of the time. A 
healthy person staying in this environment may be infected with TB.
•  Duration of exposure: The longer one stays with an infected 
person who coughs droplet nuclei, the more likely one is to become 
infected with TB. One TB patient can infect ten close contacts in 
one year. 
Once inhaled, TB bacilli travel to the lung alveoli and establish 
infection. Within 2–12 weeks after infection, immune response limits 
activity; infection becomes detectable but some bacteria survive 
and remain dormant but viable for years. This is referred to as latent 
TB infection (LTBI). Persons with LTBI are asymptomatic and non-
infectious. The majority of people born and living in Africa have had 
LTBI before completing primary school. The truth is that they remain 
asymptomatic mainly because of their good immune status as well as 
the above factors. LTBI progresses to TB disease in a small number of 
persons soon after infection. It is worth noting that 5–10% of persons 
with untreated LTBI will develop TB disease or active TB sometime 
during their lifetime. However, once a person becomes HIV positive, 
the risk increases to 10% per year to develop TB.
Symptoms and signs
Pulmonary tuberculosis should be suspected in patients coughing for 
more than two weeks. The cough is often productive (occasionally 
blood-stained) but sometimes dry. The symptoms and signs of TB are 
non-specific to the disease as these may be found in other diseases. 
Every patient who has been coughing for 2 weeks or more needs to be 
offered a TB sputum test unless the cause of the coughing is known. 
It is important to note that TB has been diagnosed among patients 
coughing for less than 2 weeks. The list of symptoms and signs are 
listed in Table I.
Table I: Symptoms of tuberculosis
• Cough (more than 2 weeks)
• Unintentional loss of weight (LOW)
• Loss of appetite
• Asthenia
• Nocturnal fever with night sweats for 2 weeks or more
• Shortness of breath
• Chest pain
Approach to the diagnosis of tuberculosis
Tuberculosis is suspected if a patient presents with the symptoms and 
signs in Table I and confirmed by laboratory tests. The main laboratory 
tests available include TB microscopy, TB culture and TB drug 
susceptibility tests. 
TB microscopy
TB microscopy is the cornerstone of TB diagnosis. The two methods 
available are the Ziehl-Neelson (ZN) and fluorescent auramine 
staining. The acid-fast staining procedure depends on the ability of 
mycobacteria to retain these dyes when treated with acid and alcohol 
solutions. The auramine is more sensitive than the ZN staining and 
TB microscopy has a sensitivity of 60%. It may be as low as 37% in 
patients with advanced HIV (Figures 1a and 1b).
Figures 1a and 1b:  ZN stain and auramine stain showing Mycobacterium 
tuberculosis bacilli
It is worth noting that even among patients with advanced HIV, 
smear-positive TB is more common than smear-negative TB hence 
TB microscopy still has a role in diagnosing TB. Two sputum samples 
are required from the patient who is coughing. The first specimen 
is collected at the first visit, as soon as possible after the medical 
consultation. The family practitioner needs to educate the patient on 
how to collect this sputum specimen under supervision within the 
healthcare facility. Toilets, consulting rooms or corridors are not suitable 
areas for collection of sputum as these expose other patients to the 
disease. Sputum collection should take place outside the building or in 
a dedicated room with all infection control precautions taken to protect 
the family practitioner and clinic staff from exposure. The second 
specimen should be collected into a sputum container given to the 
patient as an early morning specimen at home, the following day. The 
diagnosis of smear positive tuberculosis is made when acid-fast bacilli 
(AFB) are found on microscopy.
TB culture
TB culture is more sensitive than smear microscopy in detecting TB 
among patients with TB symptoms and signs. All specimens with a 
negative TB microscopy should undergo a TB culture. TB culture is 
done on a solid medium such as Lowenstein-Jensen, a liquid medium 
such as the semi-automated radiometric systems (e.g. BACTEC 460), 
or an automated non-radiometric system (e.g. MGIT). Liquid media 
have a shorter turn-around time compared to solid media.
TB drug susceptibility test
This test is used to determine susceptibility or resistance of first and 
second line anti-TB drugs. Family practitioners will generally request a 
DST for first-line drugs. The following patients must have a DST for at 
least rifampicin, isoniazid (INH) and ethambutol) routinely7:
• All newly diagnosed re-treatment patients
•  TB patients who remain sputum smear-positive after two months of 
treatment (new patients) 
• Symptomatic close contacts of confirmed MDR-TB patients
•  Symptomatic individuals from high risk groups (healthcare workers 
including laboratory staff, prisoners)
• HIV patients in MDR-TB high burden areas
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Other tests:
Chest X-rays
These are quick to obtain but their findings are not specific for 
TB. Fungal infections, malignancies, old TB lesions such as lung 
destruction or fibrosis may be misleading. Chest X-rays may be 
used to assist a family practitioner if a TB suspect remains TB smear 
microscopy negative. In addition, it is used as a tool to assess the 
patient’s response to TB or MDR-TB treatment, to help diagnose 
complications or other lung diseases, and is very useful in the 
diagnosis TB of in children although it may not be used alone as other 
parameters have to be considered.
Tuberculin Skin Test (TST)
This test is of little clinical value in our population, which has a high 
incidence of TB. It measures the delayed type hypersensitivity 
response to a purified mix of mycobacterial antigens, purified 
protein derivative (PPD).  PPD is composed of antigens found in 
Mycobacterium tuberculosis and Mycobacterium bovis (BCG) and 
other mycobacteria. Hence, a positive TST is non-specific to latent 
and active TB. Severe immunosuppression, HIV, and malnutrition 
may lead to decreased sensitivity of TST. Although it remains an 
important tool for TB diagnosis in children, TST may also be used to 
determine who should be given INH prophylaxis therapy in order to 
reduce progression of latent TB to active disease by 60% reduction in 
progression to active TB in people who test TST positive. 
Treatment of TB
The mainstay of treatment in TB is effective multidrug antimicrobial 
chemotherapy.8 The treatment has two phases namely the intensive 
and continuation phases. The first-line drugs are isoniazid, rifampicin, 
ethambutol and pyrazinamide. 
Adherence is critical to prevent resistance.4 
The strategy used to achieve adherence is the Directly Observed 
Therapy Short-course Strategy (DOTS). DOTS-Plus was later 
developed for MDR-TB. DOTS is not just about observing the patient 
swallowing his/her tablets. It has the following five components:
•  Sustained political commitment, which is needed to establish the 
following four components.
•  A rational case-finding strategy including accurate, timely diagnosis 
through quality-assured culture and DST. 
•  Appropriate treatment strategies that use second-line drugs under 
proper case management conditions.
• Uninterrupted supply of quality-assured anti-tuberculosis drugs.
• Standardised recording and reporting system.  
For newly diagnosed TB patients, the treatment has two phases:
•  Intensive phase (2 months): This phase consists of four 
first-line drugs, which are rifampicin, isoniazid, ethambutol and 
pyrazinamide. These drugs are taken orally for two months.
•  Continuation phase (4 months): This phase entails oral treatment 
using rifampicin and isoniazid for 4 months.
For re-treatment patients (relapses, defaulters), the two phases are 
longer in duration as follows:
•  Intensive phase (3 months): Rifampicin, isoniazid, ethambutol 
and pyrazinamide are given orally for three months plus 
intramuscular injection of streptomycin during the first two months
•  Continuation phase (5 months): This phase consists of 
rifampicin, isoniazid and ethambutol given for 5 months.
The above regimens are standard regimens for patients suffering from 
the commonest type of TB, which is pulmonary TB. 
The classification and grouping of TB drugs are listed in Tables II and 
III respectively.
Table II: Classification of TB drugs
Class Drugs
1. First-line drugs rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin 
2. Second-line drugs:
a. Injectables kanamycin, capreomycin, amikacin 
b. Orals
ofloxacin, levofloxacin, moxifloxacin and  
gatifloxacin, ethionamide, protionamide, 
cycloserine, terizidone,  p-aminosalicylic acid 
3. Possible reinforcing drugs
amoxicillin/clavulanate, clofazimine, 
clarithromycin, linezolid, thioacetazone,  
imipenem, high-dose INH
Table III: Grouping of TB drugs
Group Anti-TB agents Drugs
1 First-line oral isoniazid, rifampicin, ethambutol, and pyrazinamide 
2 Injectables streptomycin, kanamycin, amikacin, capreomycin and viomycin 
3 Fluoroquinolones ofloxacin, levofloxacin, moxifloxacin and  gatifloxacin  




5 Antituberculosis agents with unclear efficacy 
clofazimine, amoxicillin/clavulanate, 
thioacetazone, imipenem, high-dose 
INH, clarithromycin, linezolid 
TB patients’ rights
The patient’s Charter for Tuberculosis Care makes provision for 
patient’s rights, which are9:
•  Care: TB patients have a right to free and equitable access to TB 
care, from diagnosis to treatment without discrimination, regardless 
of their circumstances.
•  Dignity: TB patients have to be treated with respect and dignity. 
The environment of their treatment must also be dignified, with 
moral support from family, friends and the community. 
•  Information: TB patients have a right to information about 
available health care services for tuberculosis, responsibilities, 
engagements and direct as well as indirect costs. They also need 
to get information about their prognosis meaning an opinion as to 
the likely future course of the illness, treatment, and risks attached 
and appropriate alternatives. Medicines names, dosages and side-
effects need to be communicated. Access to medical information 
related to the patient’s condition and treatment is a right.
•  Choice: TB patients have a right to a second opinion, with access 
to previous medical records. They have a right to accept or refuse 
surgical interventions if chemotherapy is possible. They may 
choose to take part in research programmes or not. TB patients 
have a right to be informed of the likely medical and statutory 
consequences within the context of a communicable disease.
•  Confidence: TB patients have the right to have their personal 
privacy, dignity, religious beliefs and culture respected. They have 
the right to information relating to their medical condition being kept 
confidential, and released to other authorities contingent upon the 
patient’s consent. 
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•  Justice: TB patients have a right to make a complaint through 
channels provided for this purpose by the health authorities and to 
have any complaint dealt with promptly and fairly. They have the 
right to appeal to a higher authority if the above is not respected, 
and to be informed in writing of the outcome.
•  Organisation: TB patients have the right to join or to establish 
organisations of people with or affected by TB. They have the right 
to participate as stakeholders in the development, implementation, 
monitoring and evaluation of TB policies and programmes with 
local, national and international health authorities.
•  Security: This is about the right to job security after diagnosis or 
appropriate rehabilitation upon completion of treatment. TB patients 
have the right to nutritional security or food supplements if needed 
to meet treatment requirements.
In addition to rights, patients have the responsibilities to share as much 
information as possible with healthcare workers about past illnesses 
including relevant details, to follow up prescribed treatment, contribute 
to community health by encouraging those who exhibit TB symptoms 
to seek medical advice and to show solidarity with other patients.
The role of private family practitioners in managing tuberculosis
Case finding
The health sector is divided into three sectors: popular sector, folk 
sector and professional sector.10 Some patients would have shopped 
around between the popular sector and the folk sector (e.g. traditional 
healers, faith healers etc.). Family practitioners operate at the entry 
point of patients into the professional sector. They are more likely to be 
the first to see TB patients, hence early awareness of TB issues, early 
suspicion and diagnosis are crucial in the control of TB. The private 
family practitioner has a public health role to play by notifying the 
appropriate local clinics and health centres of any suspected TB case. 
Their non inclusion in the fight against TB in South Africa needs to be 
addressed to stem the tide of the high TB incidence in the country.
Patient education 
Private family practitioners often live in their area of work; they 
know the customs and beliefs of their patients as well. They are 
much-respected members of the community. Their patients will take 
patient education on TB transmission and control conducted by them 
seriously. Family practitioners spend most of their time motivating 
people for behaviour change. The following communication skills are a 
requirement for family practitioners11: 
1. Asking questions and listening 
2. Demonstrating a caring, respectful attitude
3. Praising and encouraging the patient
4. Speaking clearly and simply
5. Encouraging the patient to ask questions
6. Asking checking questions
Beckman and Frankel studied medical consultations and found that on 
average patients were allowed to talk for a total of eighteen seconds 
before the doctor interrupted them during opening statements.12 They 
also found that most patients who were allowed to complete their 
opening statement without interruption took less than sixty seconds 
to tell their story and that the serial order of presenting issues was not 
related to their clinical importance. It is therefore difficult to educate 
someone who is not being listened to because in order to educate it 
is better to assess the level of knowledge of the patient by listening to 
him or her.
In New York City, USA, in a review of 8 000 patients with TB, regulatory 
orders were issued for less than 4%. Of the 4% that needed regulatory 
intervention, 10% were people with injection-drug use, 16% had 
alcohol abuse problems, 17% were homeless, 29% used cocaine 
and 38% had history of incarceration.13 This review shows that most 
patients do not require legal action but those few that are detained for 
treatment have the right to an attorney and could challenge an order 
for detention in court. Even if a patient did not contest the order, judicial 
authorisation for detention was required after 60 days. Thereafter, 
detention must be justified to court every 90 days. Patient education is 
one important component that will lead to treatment adherence.
Good communication enhances the doctor-patient relationship. A study 
conducted by the Medical Research Council (MRC) of South Africa 
showed that “poor relation between the health care worker and the 
MDR-TB patients” was one of the major causes of poor adherence to 
MDR-TB treatment.14 Effective verbal communication is desired but 
has its limitations. Up to 80% of patients forget what their doctor tells 
them as soon as they leave the consulting room and nearly 50% of 
what they do remember is recalled incorrectly.15 Family practitioners 
therefore need to use pamphlets, videos, DVDs, magazines and 
various forms of educational material in addition to their own interaction 
with the patients.
TB education needs to focus on educating patients on key issues such 
as: 
• What is TB?
• How is it spread? 
• How to protect the family from getting TB?
• The link between poor adherence and MDR-TB.
• Patient reassurance.
TB patient referral and follow-up
Referral is a two-way process. Family practitioners have to refer 
patients who are suspected or diagnosed with TB to their nearest 
provincial clinics or local government healthcare facilities to confirm 
and commence TB treatment. It is important to establish a good 
working relationship with identified facilities. Family practitioners in 
turn need to request feedback and arrange with these facilities so that 
patients are seen every two months by the referring family practitioner. 
It will be a good idea to see the national or provincial department 
of health provide accreditation and anti-tuberculosis medication to 
selected private family practitioners to enhance TB treatment and 
control. 
Contact tracing
The use of TB patients’ genograms and ecomaps helps to identify 
close contacts to be screened for TB. The home visit is an option 
because of busy schedules and the increasing number of TB 
patients; all close contacts may need to come to the practice for 
examination. This is possible if the contacts do not pay consultation 
fees. Contributing to the fight against TB by screening TB contacts 
free of charge is the right thing to do in reducing TB incidence in the 
community. 
Voluntary HIV counselling and testing in TB patients
Any confirmed TB patient should be offered an HIV test. It has been 
shown that only one in three TB patients is offered an HIV test in 
South Africa. In Rwanda, the proportion of TB patients tested for HIV 
increased from 82% (138/169) in 2004–2005 to 93% (240/259) in 
2005–2006 (P < 0.001).16 This is another area where South African 
family practitioners can assist the National TB Control Programme as 
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strong, harmonious relationships exist between family practitioners and 
their patients. 
Role of a multi-disciplinary team in managing TB
The family practitioner is part of a community wide network. S/he 
understands the need to involve other healthcare professionals 
such as physiotherapists, social workers, pulmonologists, laboratory 
technicians, nurses etc. There are many HIV, TB/HIV non-
governmental organisations interested in working with TB and/or HIV 
patients. This multi-disciplinary team is crucial for the success of the 
TB control programme in any country.
Conclusion
Primary health care is the backbone of the South African healthcare 
system and the district health system is the vehicle through which 
primary health care is delivered. The family practitioner is a key role 
player within the primary healthcare system and should play a more 
important role in TB control, if the high incidence is to dramatically 
reduce. TB training at medical undergraduate level needs to improve, 
continuous medical education is necessary to develop capacity among 
family practitioners and the health department should encourage the 
involvement of especially the private family practitioners in district TB 
control, which is a long overdue public-private interaction.   
I would like to thank Ms. Margaret Roper for editing this manuscript. 
Her input and support has been invaluable to the publication of this 
work.
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